Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 20:04:32·⟳ 抓取 20:07:54 +3m22s·⚡ 决策 10-08 20:09:21 +1m27s·19.0 天前
Entera Bio 预告将在 ASBMR 年会展示口服骨质疏松药 EB613 的三期试验设计
该新闻是一场未来会议的提前宣传：核心三期内容只是研究方案设计，没有疗效或安全性数据；二期阳性结果早已完成并公开，本次未提供任何新增量信息。对临床期小生物股，价格驱动来自实际数据/设计在会议现场的披露，而非『将要展示』的预告，因此当前时点不存在正期望入场理由。
📄 原文Investing.com↗ 原文
Entera Bio to present Phase 3 trial design for oral osteoporosis drug
By Investing.com Advertisement Advertisement Entera Bio to present Phase 3 trial design for oral osteoporosis drug Comp…
不做 Entera Bio Ltd.（ENTX.US）
无新增基本面事实：三期只展示研究设计、无数据读出，二期阳性结果为已知旧信息；属例行会议预告，真正催化在 10/9 与 10/11 现场，当前不具备可交易 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Entera Bio 仅预告 3 天后在 ASBMR 展示 EB613 三期『试验设计』并重展旧的二期数据，没有新临床读出或状态迁移；属于例行会议预告而非新催化，真正的观察窗口在 10/9 与 10/11，故当前 AVOID。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 low ↗
关键理由
- 三期展示物为 planned 注册研究的方案设计，不含 topline 或任何疗效/安全数据，未将资产从『二期完成』推向新状态。
- 二期达到终点及骨密度改善均为已完成、已公开信息，本条未新增数字或合作/权益变化。
主要风险
- 小市值临床期生物股波动大，若市场借会议预告投机，盘前/开盘可能出现与基本面无关的情绪化跳动。
- 10/9 二期完整数据或 10/11 三期设计若超预期才会形成真实催化，需在数据实际披露后另行研判而非提前埋伏。
先例如何影响了这次决策
对本次决策的影响:支持当前 AVOID：不据此开仓，把研判推迟到 10/9、10/11 实际披露后。
方向:不适用：本条被判定为无新增事实的会议预告，未进入需要用先例校准涨幅的交易假设。
涨幅量级:无对齐先例可用于定幅度，且三期尚无读出，不应据预告设定 tp/sl。
形态:临床期小盘股对『将展示研究设计』类例行预告通常缺乏持续基本面反应，真正波动集中在数据现场。
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 17 ms
{"result": "search_processed_events:agent query=`entera bio eb613 phase 2 data asbmr october 2026 | entera bio eb613 phase 3 study design asbmr 2026 presentation | entx oral pth(1-34) osteoporosis phase 3 registrational poster`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent q - fetch_decision_experience 成功 stock_tools HTTP · 7 ms
{
原文全文
展开原文 · 7,455 字
Entera Bio to present Phase 3 trial design for oral osteoporosis drug By Investing.com
Advertisement
Advertisement
Entera Bio to present Phase 3 trial design for oral osteoporosis drug
Company News
Published
Oct 08, 2026, 08:04 AM
Entera Bio to present Phase 3 trial design for oral osteoporosis drug
View all comments (0)
0
Entera Bio to present Phase 3 trial design for oral osteoporosis drug
View all comments (0)
0
© Reuters
In this article:
ENTX
-0.79%
TEL AVIV, Israel -
Entera Bio
Ltd. (
NASDAQ:ENTX
) announced that a presentation detailing the Phase 3 study design for EB613, an oral tablet form of PTH(1-34), will be presented at the American Society for Bone and Mineral Research Annual Meeting from October 9-12, 2026, in Boston, according to a press release statement.
The presentation, titled "EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for the Treatment of Osteoporosis: Phase 3 Study Design," will be delivered as a late-breaking poster on Sunday, October 11, 2026. Dr. Felicia Cosman, Professor of Medicine at Columbia University, will lead the presentation outlining the study design for the planned randomized, double-blind, placebo-controlled Phase 3 registrational study evaluating EB613 in postmenopausal women with osteoporosis.
The company will also present Phase 2 clinical data for EB613 during a Plenary Poster presentation on Friday, October 9, 2026, evaluating treatment effects in postmenopausal women with osteoporosis at high risk of fracture.
Entera completed a Phase 2, six-month, 161-patient, placebo-controlled study that met biomarker and bone mineral density endpoints in women with postmenopausal osteoporosis or low bone mineral density. The study showed dose-proportional increases in biochemical markers of bone formation, reductions in markers of bone resorption, and increases in lumbar spine, total hip, and femoral neck bone mineral density.
EB613 is being developed as an oral, once-daily tablet treatment for osteoporosis. The company states that all currently available anabolic therapies for osteoporosis are administered by subcutaneous injection.
Entera Bio is a clinical stage company developing oral peptide and protein replacement therapies using its N-Tab technology platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Entera Bio to present Phase 3 trial design for oral osteoporosis drug
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
50,830.10
-349.1
-0.68%
US 500
7,771.20
-30.5
-0.39%
Dow Jones
51,179.87
-341.41
-0.66%
S&P 500
7,801.77
-17.16
-0.22%
Nasdaq
27,538.69
-61.19
-0.22%
S&P 500 VIX
15.71
+0.63
+4.18%
Dollar Index
102.14
+0.127
+0.12%
Crude Oil WTI Futures
92.30
+4.02
+4.55%
Brent Oil Futures
104.75
+4.55
+4.54%
Natural Gas Futures
3.27
+0.067
+2.09%
Gold Futures
4,151.84
+11.14
+0.27%
Silver Futures
59.208
-1.086
-1.80%
Copper Futures
6.6508
+0.0013
+0.02%
US Soybeans Futures
1,294.75
-2.25
-0.17%
U.S. 10Y
5.329
+0.051
+0.97%
U.S. 30Y
5.702
+0.041
+0.72%
U.S. 5Y
5.075
+0.054
+1.08%
U.S. 3M
4.148
+0.007
+0.17%
US 10Y T-Note Futures
104.13
-0.36
-0.34%
Euro Bund Futures
120.67
-0.14
-0.12%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.67
+3.04
+0.91%
NVDA
237.47
-1.77
-0.74%
GOOGL
350.50
+2.82
+0.81%
TSLA
377.81
-2.87
-0.75%
AMZN
259.92
+3.63
+1.42%
NFLX
69.70
+1.01
+1.47%
META
721.31
-17.57
-2.38%
Advertisement
Most Popular Articles
News
Analysis
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oil prices surge amid Mideast shipping attacks, U.S. Gulf coast disruptions
By Investing.co
...
Oct 08, 2026
AI debt deal wave reports; Applied Digital reports - what’s moving markets
By Investing.co
...
Oct 08, 2026
Wall Street posts first red session of October a day after notching a record close
By Investing.co
...
Oct 08, 2026
Samsung shares fall as record Q3 profit misses lofty expectations
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
Q4 2026 Commodites Forecast: Will Gold and Silver Find a Bottom?
By Jeremy Wagne
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
SPCX
167.60
-2.51%
77.47M
AMD
645.86
-0.55%
18.56M
AAPL
336.67
+0.91%
34.15M
TSLA
377.81
-0.75%
25.59M
Name
Last
Chg. %
Vol.
NRG
108.61
+4.84%
5.39M
MRNA
196.48
+4.81%
14.64M
MU
1,088.00
+4.06%
30.86M
CTVA
14.45
+3.88%
41.33M
VST
166.72
+3.88%
12.01M
SMCI
44.94
+3.41%
40.54M
NTAP
235.77
+3.20%
3.00M
Name
Last
Chg. %
Vol.
MSTR
153.37
-6.79%
21.67M
SKYD
8.89
-6.72%
43.30M
CAT
813.83
-5.75%
3.34M
MHK
119.18
-5.45%
1.70M
NBIS
237.15
-5.09%
18.05M
CRWD
265.44
-4.81%
8.81M
BLDR
53.55
-4.75%
2.36M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
SPCX
167.60
-2.51%
77.47M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
APLD
23.810
-6.04%
48.76M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Entera Bio to present Phase 3 trial design for oral osteoporosis drug
Company News
Published
Oct 08, 2026, 08:04 AM
Entera Bio to present Phase 3 trial design for oral osteoporosis drug
View all comments (0)
0
Entera Bio to present Phase 3 trial design for oral osteoporosis drug
View all comments (0)
0
© Reuters
In this article:
ENTX
-0.79%
TEL AVIV, Israel -
Entera Bio
Ltd. (
NASDAQ:ENTX
) announced that a presentation detailing the Phase 3 study design for EB613, an oral tablet form of PTH(1-34), will be presented at the American Society for Bone and Mineral Research Annual Meeting from October 9-12, 2026, in Boston, according to a press release statement.
The presentation, titled "EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for the Treatment of Osteoporosis: Phase 3 Study Design," will be delivered as a late-breaking poster on Sunday, October 11, 2026. Dr. Felicia Cosman, Professor of Medicine at Columbia University, will lead the presentation outlining the study design for the planned randomized, double-blind, placebo-controlled Phase 3 registrational study evaluating EB613 in postmenopausal women with osteoporosis.
The company will also present Phase 2 clinical data for EB613 during a Plenary Poster presentation on Friday, October 9, 2026, evaluating treatment effects in postmenopausal women with osteoporosis at high risk of fracture.
Entera completed a Phase 2, six-month, 161-patient, placebo-controlled study that met biomarker and bone mineral density endpoints in women with postmenopausal osteoporosis or low bone mineral density. The study showed dose-proportional increases in biochemical markers of bone formation, reductions in markers of bone resorption, and increases in lumbar spine, total hip, and femoral neck bone mineral density.
EB613 is being developed as an oral, once-daily tablet treatment for osteoporosis. The company states that all currently available anabolic therapies for osteoporosis are administered by subcutaneous injection.
Entera Bio is a clinical stage company developing oral peptide and protein replacement therapies using its N-Tab technology platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Entera Bio to present Phase 3 trial design for oral osteoporosis drug
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
50,830.10
-349.1
-0.68%
US 500
7,771.20
-30.5
-0.39%
Dow Jones
51,179.87
-341.41
-0.66%
S&P 500
7,801.77
-17.16
-0.22%
Nasdaq
27,538.69
-61.19
-0.22%
S&P 500 VIX
15.71
+0.63
+4.18%
Dollar Index
102.14
+0.127
+0.12%
Crude Oil WTI Futures
92.30
+4.02
+4.55%
Brent Oil Futures
104.75
+4.55
+4.54%
Natural Gas Futures
3.27
+0.067
+2.09%
Gold Futures
4,151.84
+11.14
+0.27%
Silver Futures
59.208
-1.086
-1.80%
Copper Futures
6.6508
+0.0013
+0.02%
US Soybeans Futures
1,294.75
-2.25
-0.17%
U.S. 10Y
5.329
+0.051
+0.97%
U.S. 30Y
5.702
+0.041
+0.72%
U.S. 5Y
5.075
+0.054
+1.08%
U.S. 3M
4.148
+0.007
+0.17%
US 10Y T-Note Futures
104.13
-0.36
-0.34%
Euro Bund Futures
120.67
-0.14
-0.12%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.67
+3.04
+0.91%
NVDA
237.47
-1.77
-0.74%
GOOGL
350.50
+2.82
+0.81%
TSLA
377.81
-2.87
-0.75%
AMZN
259.92
+3.63
+1.42%
NFLX
69.70
+1.01
+1.47%
META
721.31
-17.57
-2.38%
Advertisement
Most Popular Articles
News
Analysis
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oil prices surge amid Mideast shipping attacks, U.S. Gulf coast disruptions
By Investing.co
...
Oct 08, 2026
AI debt deal wave reports; Applied Digital reports - what’s moving markets
By Investing.co
...
Oct 08, 2026
Wall Street posts first red session of October a day after notching a record close
By Investing.co
...
Oct 08, 2026
Samsung shares fall as record Q3 profit misses lofty expectations
By Investing.co
...
Oct 08, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
Q4 2026 Commodites Forecast: Will Gold and Silver Find a Bottom?
By Jeremy Wagne
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
SPCX
167.60
-2.51%
77.47M
AMD
645.86
-0.55%
18.56M
AAPL
336.67
+0.91%
34.15M
TSLA
377.81
-0.75%
25.59M
Name
Last
Chg. %
Vol.
NRG
108.61
+4.84%
5.39M
MRNA
196.48
+4.81%
14.64M
MU
1,088.00
+4.06%
30.86M
CTVA
14.45
+3.88%
41.33M
VST
166.72
+3.88%
12.01M
SMCI
44.94
+3.41%
40.54M
NTAP
235.77
+3.20%
3.00M
Name
Last
Chg. %
Vol.
MSTR
153.37
-6.79%
21.67M
SKYD
8.89
-6.72%
43.30M
CAT
813.83
-5.75%
3.34M
MHK
119.18
-5.45%
1.70M
NBIS
237.15
-5.09%
18.05M
CRWD
265.44
-4.81%
8.81M
BLDR
53.55
-4.75%
2.36M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
SPCX
167.60
-2.51%
77.47M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
APLD
23.810
-6.04%
48.76M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。